Drugs / TGX-007
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07346144 | Apr 2026 → Mar 2030 expected | glioblastoma | Trogenix ltd | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-05-28 | Trogenix ltd | Trogenix doses first patient in Phase I/II clinical trial of TGX-007 gene therapy for glioblastoma trogenix.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TGX-007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07346144 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “gene therapy drug delivered by a harmless adeno-associated virus (AAV) vector” NCT07346144 ↗ |
| Route | Other | “direct intratumoural injection” NCT07346144 ↗ |